Note 19 Non-current finanical assets

Download Excel

          Parent Company
Receivables from Group companies 2021-12-31 2020-12-31
Opening balance 1,709.2 1,278.0
Increase during the year 5,090.0 731.9
Decrease during the year -210.4 -300.7
Carrying amount at year-end 6,588.8 1,709.2
             
Specification of interests in Group companies Country Number of shares Quotient value Holding % Carrying amount 2021-12-31 Carrying amount 2020-12-31
AddLife Development AB Sweden 1,000 100 100% 389.1 389.1
 
Interests in Group companies Parent Company
Accumulated cost 2021 2020
Opening balance 389.1 805.6
Acquisitions for the year 4,478.7 –
Disposals for the year¹ -4,478.7 -416.5
Closing balance 389.1 389.1
¹ Internal sale year 2021 of Primacy Healthcare 21 Limited and AddVision Holding GmbH and year 2020 of Biomedica Holding GmbH to AddLife Development AB

Download Excel

Indirect ownership
Indirect ownership Ownership   Indirect ownership Ownership   Indirect ownership Ownership
Biomedica Medizinprodukte GmbH 100%   Svan Care AB 100%   BioNordika (Denmark) A/S 100%
Biomedica Services AG 100%   Esthe-Tech AB 100%   BioNordika Bergman AS 100%
Euromed Swiss AG 100%   V-tech AB 100%   BioNordika (Sweden) AB 100%
Biomedis d.o.o. 100%   Väinö Korpinen Oy 100%   BioNordika (Finland) Oy 100%
Biomedica MP d.o.o. 100%   Triolab Oy 100%   Dach Medical Group Holding AG 100%
Biomedica Dijagnostika doo 100%   Triolab AB 100%   Dach Austria Medical Group GmbH 100%
Biomedica d.o.o. 100%   Triolab (Baltics) Oy 100%   Dach Switzerland Medical Group GmbH 100%
Biomedica Bulgaria ood 100%   LabRobot Products AB 100%   D-A-CH Germany Medical Group GmbH 100%
Biomedica Medizinprodukte Romania SRL 100%   BergmanLabora AB 100%   Hepro AS 100%
Biomedica Hungaria Kft. 100%   Biolin Scientific AB 100%   Ropox A/S 100%
Biomedica CS s.r.o. 100%   Biolin Scientific China 100%   Zafe Care Systems AB 100%
Biomedica Poland Sp. Zo.o. 100%   Biolin Scientific Oy 100%   Biomedica Italia s.r.l 100%
Biomedica Dijagnostika d.o.o.el 100%   Biolin Scientific LTD 100%   Primacy Healthcare 21 Limited 100%
Biomedica Slovakita s.r.o. 80%   Holm & Halby A/S 100%   Aquilant Northern Ireland Limited 100%
Mediplast AB 100%   Ocellus Vision Holding AG 100%   Aquilant Limited 100%
Mediplast AS 100%   Medilas AG 100%   Cardio Solutions (UK) Limited 100%
Mediplast Sataside Oy 100%   Polytech Ophthalmologie AG 100%   Aquilant Endoscopy Limited 100%
Mediplast S.r.l 100%   Polytech Domilens GmbH 100%   Healtcare Acquisitions Limited 100%
Mediplast Benelux B.V. 100%   M.E.D. Medical Products GmbH, Germany 100%   Medscope Limited 100%
Mediplast GmbH 100%   Vision Ophthalmology Holding One GmbH 100%   Tools For Living (Ireland) Limited 100%
Mediplast A/S 100%   Vision Ophthalmology Group GmbH 100%   Lyncare Systems Limited 100%
Mediplast Iberia SL 100%   Spectrum Ophthalmology Ltd 100%   Healthcare 21 (UK) Limited 100%
Hospidana A/S 100%   POLYMED Polska Sp.z.oo 75%   Healthcare 21 (DE) GmbH 100%
Fenno Medical Oy 100%   Visop Nordic AB 100%   Healthcare 21 (AT) GmbH 100%
TechniPro PulmoMed Pty Ltd 100%   SSCP Blink BidCo Ltd 100%   Primacy Healthcare 21 International Limited 100%
Fischer Medical AS 100%   Vision Pharmaceuticals Ltd 100%   Asset Tracker Solutions Limited 100%
Camanio AB 100%   MALA Holding B.V. 100%   Aquilant Scientific (ROI) Limited 100%
Bestic AB 100%   Bio-Connect B.V. 100%   Aquilant Medical (ROI) Limited 100%
Lab-Vent Controls A/S 100%   Bio-Connect Diagnostics B.V. 100%   Aquilant Pharmaceuticals Limited 100%
Immuno Diagnostics Oy 100%   Bio-Connect Services B.V. 100%   Aquilant Analytical Sciences Limited 100%
Bergman Diagnostika AS 100%   European Warehousing Services B.V. 100%   Xograph Healthcare Limited 100%
EuroClone S.p.A. 100%   Pharma-Connect B.V. 100%   Xograph Healthcare (Ireland) Limited 100%
Funksjonsutstyr AS 76%   N.V. Forlab SA 100%   Xograph Group Holdings Limited 100%

Accounting principle

Interests in Group companies are recognised in the Parent Company using the cost method, which means that transaction costs are included in the carrying amount for holdings in subsidiaries. Any changes in liabilities for contingent consideration are added to or reduce the (acquisition) cost. In the Group, transaction costs are expensed and changes in liabilities for contingent considerations are entered as income or expense. Shareholder contributions provided by the Parent Company are recognized in shares, when impairment is not required.